- Home
- NA vs LUCD Comparison
NA vs LUCD Comparison
Compare NA & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- LUCD
- Stock Information
- Founded
- NA 2019
- LUCD 2018
- Country
- NA China
- LUCD United States
- Employees
- NA N/A
- LUCD N/A
- Industry
- NA Semiconductors
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NA Technology
- LUCD Health Care
- Exchange
- NA Nasdaq
- LUCD Nasdaq
- Market Cap
- NA 95.7M
- LUCD 108.0M
- IPO Year
- NA 2022
- LUCD 2021
- Fundamental
- Price
- NA $4.77
- LUCD $1.27
- Analyst Decision
- NA
- LUCD Strong Buy
- Analyst Count
- NA 0
- LUCD 5
- Target Price
- NA N/A
- LUCD $3.70
- AVG Volume (30 Days)
- NA 115.9K
- LUCD 1.3M
- Earning Date
- NA 08-15-2025
- LUCD 11-12-2025
- Dividend Yield
- NA N/A
- LUCD N/A
- EPS Growth
- NA N/A
- LUCD N/A
- EPS
- NA N/A
- LUCD N/A
- Revenue
- NA $3,369,693.00
- LUCD $4,360,000.00
- Revenue This Year
- NA N/A
- LUCD $13.90
- Revenue Next Year
- NA N/A
- LUCD $154.24
- P/E Ratio
- NA N/A
- LUCD N/A
- Revenue Growth
- NA N/A
- LUCD 14.74
- 52 Week Low
- NA $2.77
- LUCD $0.75
- 52 Week High
- NA $31.48
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- NA 39.49
- LUCD 60.70
- Support Level
- NA $4.61
- LUCD $1.17
- Resistance Level
- NA $5.97
- LUCD $1.27
- Average True Range (ATR)
- NA 0.36
- LUCD 0.07
- MACD
- NA -0.07
- LUCD 0.01
- Stochastic Oscillator
- NA 11.76
- LUCD 86.67
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.